2.1 Study participants
415 patients (age 18-65 years) with HDM-induced AR with or without
asthma were recruited from 71 general practices or outpatient clinics of
allergologists, dermatologists, Ear-Nose-Throat (ENT) specialists or
pulmonologists in the Netherlands between September 2017 and March 2019.
A patient was diagnosed with HDM allergy, when having a positive skin
prick test to HDM extract or allergen specific HDM IgE level of ³ 0.35
IU/mL next to an appropriate clinical history. The decision to initiate
treatment with HDM SLIT-tablet was made at the discretion of the
physician. Key discontinuation criteria were patient-based decision or
treatment-related adverse event (AE). The study was approved by the
Dutch Clinical Research Federation/nWMO Advisory Committee Twente (no.
NWMO17.04.017) and the applicable ethics committees and institutional
review boards. All patients gave written informed consent. The study
complies with the Declaration of Helsinki.